"Designing Growth Strategies is in our DNA"
In January 2019, the FDA approved the third ever oncology biosimilar called Ontruzant (trastuzumab-dttb) of Samsung Bioepis which is a Herceptin referencing biosimilar trastuzumab, indicated for the treatment of multiple forms of cancers such as gastric cancer. The incidences of cancer cases are rising worldwide, exerting pressure on the financial resources of the individual diagnosed. The treatment of cancer using biologic drugs is being increasing, due to the high effectiveness of the drug and comparatively lesser side effects, however biologic drugs are expensive, leading to greater treatment costs per patient. The high cost coupled with the patents of many of these biologic agents expiring has led to the innovation of biosimilars of the biologic agents. Biosimilars are very comparable to their reference products but due to their size and complexity, are not entirely identical. But the products are clinically as effective and safe as the innovator biologic agents. Biosimilars thus represent greater cost savings but they are subjected to the regulatory agencies approval and require more training for the clinician handling it. According to the estimates by The Agency for Healthcare Research and Quality (AHRQ), the direct medical costs for cancer in the US in 2015 were approxiamtely $80 billion. This has led to increased negative scrutiny on treatments which only achieve marginal benefits. The growth for the biosimilars is also expected to fuel by the expiration of the patents of a large number of biologics. These factors are expected to contribute to the considerable and fuel the growth of the global oncology biosimilars market.
One of the key driving factors for the global oncology biosimilars market is the increasing prevalence of various forms of cancers and the associated need of highly effective and precise treatment options. With wrong and imprecise treatment, which is also expensive, the patient also faces an increased burden of cost.
To get information on various segments, share your queries with us
The factor that is expected to inhibit the growth of the market is the complexities in manufacturing that are associated with oncology biosimilars products. Regulatory and clinical hurdles might also impact the growth of the market due to delays in product approvals, owing to biosimilars have to go undergo additional clinical trials before their regulatory approvals.
Some of the major companies that are present in the global oncology biosimilars market are Sandoz International GmbH, Celltrion Inc., Pfizer Inc., Amgen Inc., Samsung Bioepis, Biogen International, Merck & Co., Inc., Coherus Biosciences and other players.
By Drug Class
· mAb (monoclonal antibodies)
· Hematopoietic Agents
By Type of Cancer
· Lung Cancer
· Breast Cancer
· Prostate Cancer
· Stomach Cancer
· Cervical Cancer
· Blood Cancer
· Brain Cancer
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
At present, monoclonal antibodies & G-CSF account for the largest proportion of the market, due to its high adoption globally.
The global oncology biosimilars market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America and Europe contribute as the biggest regional markets because they have laid down the foundations of the regulatory standards for the oncology biosimilars and these are the markets where a majority of the clinical trials of the biosimilars are ongoing. The prevalence of cancers in North America and Europe is high, leading to more demand for effective treatments. The Asia Pacific is an emerging market, especially Korea, China, and India, have made progress in oncology biosimilars. They also represent the future potential of the market due to the large population, increasing health awareness and increasing healthcare expenditure and lower production costs.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm